Nom du produit:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline

IUPAC Name:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline

CAS:2448173-20-2
Formule moléculaire:C16H17N5O
Pureté:95%+
Numéro de catalogue:CM1045041
Poids moléculaire:295.35

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2448173-20-2
Formule moléculaire:C16H17N5O
Point de fusion:-
Code SMILES:NC1=CC=C(C=C1)C1=CC2=C(N=CN=C2N1)N1CCOCC1
Densité:
Numéro de catalogue:CM1045041
Poids moléculaire:295.35
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

Related Products